Notable highlights in 2021 include:
- Published compelling preclinical data from Yale University in The Journal of Clinical Investigation—Insight confirming the ability of PAT-DX1 to cross the blood-brain barrier, and supporting its potential to be used for primary and secondary brain cancers.
- Announced a successful preclinical study from the Garvan Institute showing that PAT-DX1 is able to slow tumour growth and increase survival in an animal model of pancreatic cancer.
- Released new data demonstrating that PAT-DX3 can be used as a targeting agent for antibody drug conjugates (ADC) to deliver anti-cancer drugs to tumours in an animal model.
- Established a collaboration with Imagion Biosystems to develop new, improved imaging agents for brain cancers using Patrys’ deoxymabs.
- Expanded Patrys’ intellectual property portfolio with the granting of a US patent for our deoxymab assets.
- A successful $7.8 million capital raise to support further research and development activities.
- Forums
- ASX - By Stock
- Ann: Change of Director's Interest Notices x2
Notable highlights in 2021 include: Published compelling...
-
- There are more pages in this discussion • 126 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 2053666 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 3325244 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 2053666 | 0.006 |
16 | 8665158 | 0.005 |
11 | 6064000 | 0.004 |
14 | 6400766 | 0.003 |
5 | 2522000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 3325244 | 5 |
0.008 | 2781393 | 7 |
0.009 | 1080000 | 2 |
0.010 | 1396000 | 6 |
0.012 | 1292407 | 3 |
Last trade - 16.12pm 19/08/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |
Day chart unavailable